Fundraising Fox
Bioxytran
OTC: BIXTNewton, US · Founded 2018 · Nevada corporation
Find your way into Bioxytran
Sign up to see every warm intro you have to Bioxytran
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Bioxytran team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Bioxytran is a clinical-stage pharmaceutical company developing carbohydrate-based drug platforms in glycovirology, hypoxia, and degenerative diseases, using galectin inhibitors to block viral replication and oxygen-carrying treatments for conditions such as stroke, wounds, and brain damage. Its therapies target viruses, hypoxic conditions, necrosis, and degenerative diseases.
Founders & leadership
Bioxytran was founded in 2018 by David Platt.
DP
David PlattFounder · Chief Executive OfficerFounder of Bioxytran, David Platt has expertise in organic chemistry, chemical engineering, medicinal chemistry, and drug design.
SO
Soderquist OlaExecutive
AH
Alan HobermanNamed on SEC filing
DH
Dale H ConawayNamed on SEC filing
HJ
Henry J. EsberNamed on SEC filing
AN
Anders N. UtterNamed on SEC filing
Funding
SEC filings, press & company announcements$6.4M disclosed across 7 of 9 rounds · 2018–2026
- Undisclosed amountprivate placementMar 2026Source ↗
▶$130KraisedMar 2023 · 3 investors · BiotechnologyRule 506(b)
▶$130KraisedMar 2023 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ola SoderquistExecutive Officer
- Offering amount
- $6M
- Amount sold
- $130K
- Minimum investment
- $25K
- Sales commissions
- $1M
- Placement agents
- Vestec Securities, Inc.
- First sale
- Nov 2022
- Incorporated
- Corporation, Nevada, 2018
- Federal exemptions
- 06b
▶$600KraisedAug 2022 · 1 investors · BiotechnologyRule 506(b)
▶$600KraisedAug 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ola SoderquistExecutive Officer
- Offering amount
- $600K
- Amount sold
- $600K
- Minimum investment
- $600K
- Sales commissions
- $38.6K
- Placement agents
- WallachBeth Capital LLC
- First sale
- Aug 2022
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$1.5MraisedJan 2022 · 34 investors · BiotechnologyRule 506(b)
▶$1.5MraisedJan 2022 · 34 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ola SoderquistExecutive Officer
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- Minimum investment
- $25K
- Sales commissions
- $128.3K
- Placement agents
- WallachBeth Capital LLC
- First sale
- Jan 2022
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$3.3MraisedJul 2021 · 9 investors · BiotechnologyRule 506(b)
▶$3.3MraisedJul 2021 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ola SoderquistExecutive Officer
- Offering amount
- $3.3M
- Amount sold
- $3.3M
- Minimum investment
- $20K
- Sales commissions
- $119.8K
- Placement agents
- WallachBeth Capital LLC
- First sale
- May 2021
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$332.3KraisedNov 2019 · 1 investors · BiotechnologyRule 506(b)
▶$332.3KraisedNov 2019 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Henry J. EsberDirector
- Anders N. UtterDirector
- David PlattExecutive Officer, Director
- Ola SoderquistExecutive Officer
- Alan HobermanDirector
- Dale H ConawayDirector
- Offering amount
- $1M
- Amount sold
- $332.3K
- Minimum investment
- $100K
- Finders' fees
- $35K
- Proceeds to insiders
- $20K
- Placement agents
- Aurora Capital LLC
- First sale
- Oct 2019
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$250KraisedNov 2018 · 1 investors · BiotechnologyRule 506(b)
▶$250KraisedNov 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alan HobermanDirector
- Soderquist OlaExecutive Officer
- Dale H ConawayDirector
- David PlattExecutive Officer, Director
- Henry J. EsberDirector
- Anders N. UtterDirector
- Offering amount
- $500K
- Amount sold
- $250K
- Minimum investment
- $250K
- Proceeds to insiders
- $20K
- First sale
- Oct 2018
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Bioxytran do?
- Bioxytran is a clinical-stage pharmaceutical company developing carbohydrate-based drug platforms in glycovirology, hypoxia, and degenerative diseases, using galectin inhibitors to block viral replication and oxygen-carrying treatments for conditions such as stroke, wounds, and brain damage. Its therapies target viruses, hypoxic conditions, necrosis, and degenerative diseases.
- Who founded Bioxytran?
- Bioxytran was founded by David Platt in 2018.
- How much funding has Bioxytran raised?
- Bioxytran has disclosed $6.4M raised across 7 of its 9 known rounds.
- Where is Bioxytran headquartered?
- Bioxytran is headquartered in Newton, US.